The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / ACR Convergence 2020 / Systemic Lupus Erythematosus Resource Center

Systemic Lupus Erythematosus Resource Center

Systemic lupus erythematosus (SLE or lupus) is a chronic disease that causes systemic inflammation and affects multiple organs. Who is most at risk to develop SLE, and why? How does a person transition from healthy to active lupus? How can we help patients achieve and maintain remission? These are some of the questions explored in sessions at ACR Convergence 2020.

Dozens of research abstracts on various aspects of lupus were presented during the fully virtual event, and David S. Pisetsky, MD, PhD, professor of medicine and immunology at Duke University School of Medicine in Durham, N.C., a staff rheumatologist at the Durham VA Medical Center and the very first physician editor of The Rheumatologist, highlighted a select few abstracts for us. “I have tried to highlight the context of the work and its importance,” he says.

Also, see below for TR Physician Editor Philip Seo, MD, MHS-selected coverage from ACR Convergence 2020. And we invite you to explore our collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of SLE.

ACR Convergence 2020: Systemic Lupus Erythematosus

Lupus Immunology Findings Provide Insights for Rheumatologists

ACR Convergence 2020

Chandra Mohan, MD, PhD, provided an update on the immunology behind SLE and research findings from the past decade.... [Read More]

State of the Art Session Reviews Lupus Causes, Potential Treatments

ACR CONVERGENCE 2020—Rheumatologists and patients have struggled with a lack of new therapies for systemic lupus erythematosus (SLE), but a better understanding of the underlying mechanisms behind the disease helps shed light on potential treatments. That was the theme of the ACR Convergence session State of the Art: Lupus—The Future Is Now, led by Peggy… [Read More]

Top Research in Lupus Presented at ACR Convergence 2020

ACR CONVERGENCE 2020—Held Nov. 5–9, the ACR’s first fully virtual annual meeting is a wrap, but that doesn’t mean it’s too late to catch the highlights. Dozens of research abstracts on various aspects of lupus were presented during the fully virtual event, and David S. Pisetsky, MD, PhD, professor of medicine and immunology at Duke… [Read More]

Anti-TNF Treatment Trial Encouraging for High-Risk APS Pregnancies

Early results in a phase 2 trial are finding that adding a TNF blocker to other treatment could greatly lower the risk of serious complications during pregnancy for women who have antiphospholipid syndrome with lupus anticoagulant.... [Read More]

Synopsis: Single Cell Technologies & New Insights into SLE

ACR CONVERGENCE 2020—The definition of cell type depends increasingly on a cell’s molecular features. On Friday, Nov. 6, 2020, Alex Kuo, PhD, senior scientist at Stanford University School of Medicine, Stanford, Calif., described six technologies that are relatively mature and can be used for rheumatic disease research: Rapidly developing single-cell RNA sequencing (scRNA-seq); Cellular indexing… [Read More]

Can We Predict & Prevent Pregnancy Complications in Patients with Lupus & APS?

ACR CONVERGENCE 2020—New evidence, though derived from small numbers, suggest that treatment with the TNF-inhibitor certolizumab could help improve high-risk pregnancy outcomes in women with antiphospholipid syndrome (with or without systemic lupus erythematosus) and lupus anticoagulants, an expert said. In the Phase 2 IMPACT trial, which has already enrolled 27 women and is continuing to… [Read More]

Lupus Immunology Trends Provide Insights for Rheumatologists

ACR CONVERGENCE 2020—With an understanding of the key causes that are behind immune abnormalities in systemic lupus erythematosus (SLE), rheumatologists gain insights into this disease. During the ACR Convergence session Immunology Update—The Decade in Review: 10 Steps to SLE, Chandra Mohan, MD, PhD, Hugh Roy and Lillie Cranz Cullen Endowed Professor, University of Houston, provided… [Read More]

Newer Targets Pave the Way for Future Lupus Therapies

ACR CONVERGENCE 2020—Although rheumatologists have struggled with a lack of new therapies for systemic lupus erythematosus (SLE), recent positive trial results have brought renewed hope for more treatments. That was the theme of the ACR Convergence 2020 session, State of the Art: Lupus—The Future Is Now, led by Peggy Crow, MD, the Benjamin M. Cohen… [Read More]

ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis

ACR CONVERGENCE 2020—At the annual meeting’s second Plenary Session, Saturday, Nov. 7, speakers highlighted phase 2 results of a potential new biologic for systemic lupus erythematosus (SLE), as well as data on remission maintenance in rheumatoid arthritis (RA) after withdrawal of etanercept or methotrexate. Phase 2 Trial of Monoclonal Antibody for Lupus (LILAC) Several converging… [Read More]

ACR Convergence 2020 Kicks Off: Plenary session speakers highlight racial differences in lupus & COVID-19-related findings

ACR CONVERGENCE 2020—The ACR’s first fully virtual annual meeting kicked off on Thursday, Nov. 5. During the Opening Session, ACR President Ellen M. Gravallese, MD, talked about how the specialty’s response during the pandemic has provided great hope and will help rheumatology become an even more essential specialty. At the first Plenary Session on Friday,… [Read More]

Research, Case Reports & More

Studies Examine Peripheral Nervous System Disease in Lupus Patients

Although systemic lupus erythematosus (SLE) affects both the central nervous system (CNS) and peripheral nervous system (PNS), past research has primarily focused on how lupus affects the CNS. Now, an international, inception cohort study, “Peripheral Nervous System Disease in Systemic Lupus Erythematosus,” published in Arthritis & Rheumatology, has examined different types of PNS disease to… [Read More]

What’s the Role of Epstein-Barr Virus Reactivation in Lupus Development?

A strong association between Epstein-Barr virus (EBV) infections and systemic lupus erythematosus (SLE) has been known since the 1970s. Although the etiology of SLE is not fully established, multiple genetic factors and polymorphisms in genes involved in the immune system have been implicated, with environmental factors also contributing to the development of this complex condition…. [Read More]

Duke Researchers Create a Type 1, Type 2 Lupus Disease Model

A new disease model for lupus tackles issues with fatigue and other serious conditions that, although quite common among patients, get less attention because they fall outside classic symptoms associated with inflammation, a debilitating force behind systemic lupus erythematosus (SLE). The model features subtypes to cate­gorize two main groups of symptoms into type 1, typically… [Read More]

A New Frailty Index Aids Lupus Assessment

A recently developed frailty index may be a valuable way to quantify vulnerability in patients with systemic lupus erythe­matosus (SLE), according to a study published in Arthritis & Rheumatology.1 When evaluating SLE, physicians consider a patient’s disease activity, organ damage and health-related quality of life. The Systemic Lupus International Collaborating Clinics (SLICC)/ACR Damage Index (SDI)… [Read More]

Familial Patterns in Childhood- & Adult-Onset SLE

A study examining familial patterns of systemic lupus erythematosus (SLE) found a greater decline in SLE recurrence rate by generation in childhood- than in adult-onset SLE, suggesting adult-onset SLE may be characterized by environmental risk factors.... [Read More]

The Environment Within: A Possible Link Identified Between Plasma Microbial Translocation & Autoantibody Development in 1st Degree Relatives of SLE Patients

Plasma microbial translocation, the composition of the microbiome and environmental factors may influence the development of autoantibodies in patients with systemic lupus erythematosus (SLE), according to a study comparing SLE patients with their first-degree relatives and unrelated, healthy controls.... [Read More]

How to Empower Lupus Patients Through Social Media & Online Resources

Social media connections, such as LupusChat and online resources from the ACR’s Lupus Initiative, are providing safe spaces and support for lupus patients during the COVID-19 pandemic…... [Read More]

Age-Related Blood Pressue Patterns in Lupus

Rheumatologists should not be falsely reassured by a normal mean blood pressure in lupus patients, according to a study from Johns Hopkins University that found age-related blood pressure patterns in systemic lupus erythematosus (SLE) differ from the general population and that increased diastolic blood pressure variability (BPV) is highly associated with cardiovascular events in SLE.1… [Read More]

The History of Treating Lupus with Hydroxychloroquine

nukeaf / shutterstock.com

Given how unexpectedly front and center hydroxychloroquine has been in discussions about the treatment of COVID-19 this year, it makes sense to look at how it became so central to the treatment of a rheumatologic condition. In 1991, an article appeared in The New England Journal of Medicine that would alter the way rheumatologists approached… [Read More]

Upper Limb Exercise May Improve Quality of Life for Lupus Patients

A recent study found SLE patients may improve their daily physical function, pain and overall quality of life by adding upper limb exercises to stable treatment regimens and routine care…... [Read More]

  • 1
  • 2
  • Next Page »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.